ArticleBMJ open2025
Exploring potential target drugs for vision-threatening diabetic retinopathy using the human plasma proteome: a Mendelian randomisation study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR) is a common microvascular complication of diabetes that has the potential to progress to vision-threatening DR (VTDR) even in the absence of symptoms. Plasma proteins in response to physiological and pathological conditions in the body may be intricately connected to the initiation of VTDR.
objectiveTo determine the causality between 4489 plasma proteins and the risk of VTDR to explore potential therapeutic targets for VTDR.
designA Mendelian randomisation (MR) study.
settingA two-sample MR study was performed to investigate the causality between plasma proteins and VTDR.
participantsGenetic information on plasma proteins and VTDR in European populations from IEU OpenGWAS. PRIMARY AND SECONDARY OUTCOME MEASURES: Mediation analysis was performed to evaluate the indirect impacts of plasma proteins on VTDR via related risk variables. Furthermore, the druggability and potential role of the target proteins in VTDR were explored.
resultsAccording to the MR study, 92 proteins out of 4489 plasma proteins had causal relationships with VTDR. Five potential proteins (MMP8, BST1, ARL1, MRPL33 and SDF2L1) were causally related to both VTDR and risk factors. Mediation analysis revealed that the protein-mediating effects on VTDR outcomes were achieved through risk factors (body mass index; glycated haemoglobin). Seven drugs that interacted with MMP8 were potential target drugs for VTDR.
conclusionsOur investigation elucidated the causal connections between plasma proteins, risk factors and VTDR, identified MMP8 protein as a potential drug target and highlighted seven candidate drugs. These results provide a translational framework for developing novel therapies for VTDR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.